Clinical Trial

A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-859 after single ascending doses in healthy adult volunteers.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-04
Trial Details
NCT Number NCT07736638
Lead Sponsor AbbVie
Conditions Healthy Volunteer
Enrollment 64 participants
Start Date 2026-07-28
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-03